Other adjuvants, such as resiquimod (R848), a TLR7/8 agonist, can synergize with DOX to form the in situ vaccination, resulting in sixfolds of CD8+ T cells in the tumor microenvironment and a regression rate of 40% against 4T1 tumors.[117]. Here, CD8A is linked to neoplasm.